These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 21839823

  • 1. Some pharmaceutical and inclusion properties of 2-hydroxybutyl-β-cyclodextrin derivative.
    Ishiguro T, Morishita E, Iohara D, Hirayama F, Wada K, Motoyama K, Arima H, Uekama K.
    Int J Pharm; 2011 Oct 31; 419(1-2):161-9. PubMed ID: 21839823
    [Abstract] [Full Text] [Related]

  • 2. Heptakis(2,6-di-O-methyl-3-O-acetyl)-beta-cyclodextrin: A water-soluble cyclodextrin derivative with low hemolytic activity.
    Hirayama F, Mieda S, Miyamoto Y, Arima H, Uekama K.
    J Pharm Sci; 1999 Oct 31; 88(10):970-5. PubMed ID: 10514341
    [Abstract] [Full Text] [Related]

  • 3. Some pharmaceutical properties of 3-hydroxypropyl- and 2,3-dihydroxypropyl-beta-cyclodextrins and their solubilizing and stabilizing abilities.
    Yoshida A, Yamamoto M, Irie T, Hirayama F, Uekama K.
    Chem Pharm Bull (Tokyo); 1989 Apr 31; 37(4):1059-63. PubMed ID: 2766408
    [Abstract] [Full Text] [Related]

  • 4. Involvement of PI3K-Akt-Bad pathway in apoptosis induced by 2,6-di-O-methyl-beta-cyclodextrin, not 2,6-di-O-methyl-alpha-cyclodextrin, through cholesterol depletion from lipid rafts on plasma membranes in cells.
    Motoyama K, Kameyama K, Onodera R, Araki N, Hirayama F, Uekama K, Arima H.
    Eur J Pharm Sci; 2009 Oct 08; 38(3):249-61. PubMed ID: 19664706
    [Abstract] [Full Text] [Related]

  • 5. Effect of 2,6-di-O-methyl-alpha-cyclodextrin on hemolysis and morphological change in rabbit's red blood cells.
    Motoyama K, Arima H, Toyodome H, Irie T, Hirayama F, Uekama K.
    Eur J Pharm Sci; 2006 Oct 01; 29(2):111-9. PubMed ID: 16870405
    [Abstract] [Full Text] [Related]

  • 6. Influence of preparation methodology on solid-state properties of an acidic drug-cyclodextrin system.
    Govindarajan R, Nagarsenker MS.
    J Pharm Pharmacol; 2004 Jun 01; 56(6):725-33. PubMed ID: 15231037
    [Abstract] [Full Text] [Related]

  • 7. [Use of water-soluble beta-cyclodextrin derivatives as carriers of anti-inflammatory drug biphenylylacetic acid in rectal delivery].
    Arima H, Kondo T, Irie T, Hirayama F, Uekama K, Miyaji T, Inoue Y.
    Yakugaku Zasshi; 1992 Jan 01; 112(1):65-72. PubMed ID: 1578346
    [Abstract] [Full Text] [Related]

  • 8. Inclusion complexes of tadalafil with natural and chemically modified beta-cyclodextrins. I: preparation and in-vitro evaluation.
    Badr-Eldin SM, Elkheshen SA, Ghorab MM.
    Eur J Pharm Biopharm; 2008 Nov 01; 70(3):819-27. PubMed ID: 18655829
    [Abstract] [Full Text] [Related]

  • 9. Improvement of solubility and oral bioavailability of 2-(N-cyanoimino)-5-[(E)-4-styrylbenzylidene]-4-oxothiazolidine (FPFS-410) with antidiabetic and lipid-lowering activities in dogs by 2-hydroxypropyl-beta-cyclodextrin.
    Hara T, Hirayama F, Arima H, Yamaguchi Y, Uekama K.
    Chem Pharm Bull (Tokyo); 2006 Mar 01; 54(3):344-9. PubMed ID: 16508189
    [Abstract] [Full Text] [Related]

  • 10. Formulation and biological evaluation of glimepiride-cyclodextrin-polymer systems.
    Ammar HO, Salama HA, Ghorab M, Mahmoud AA.
    Int J Pharm; 2006 Feb 17; 309(1-2):129-38. PubMed ID: 16377107
    [Abstract] [Full Text] [Related]

  • 11. Cyclodextrins as carriers for kavalactones in aqueous media: spectroscopic characterization of (S)-7,8-dihydrokavain and beta-cyclodextrin inclusion complex.
    Pescitelli G, Bilia AR, Bergonzi MC, Vincieri FF, Di Bari L.
    J Pharm Biomed Anal; 2010 Aug 01; 52(4):479-83. PubMed ID: 20185265
    [Abstract] [Full Text] [Related]

  • 12. Influence of modified cyclodextrins on solubility and percutaneous absorption of celecoxib through human skin.
    Ventura CA, Tommasini S, Falcone A, Giannone I, Paolino D, Sdrafkakis V, Mondello MR, Puglisi G.
    Int J Pharm; 2006 May 11; 314(1):37-45. PubMed ID: 16581211
    [Abstract] [Full Text] [Related]

  • 13. New cyclodextrin derivative 6-O-(2-hydroxybutyl)-beta-cyclodextrin: preparation and its application in molecular binding and recognition.
    Sun HY, Bai Y, Zhao MG, Hao AY, Xu GY, Shen J, Li JY, Sun T, Zhang HC.
    Carbohydr Res; 2009 Oct 12; 344(15):1999-2004. PubMed ID: 19703683
    [Abstract] [Full Text] [Related]

  • 14. Formation of stable hydrophilic C60 nanoparticles by 2-hydroxypropyl-β-cyclodextrin.
    Iohara D, Hirayama F, Higashi K, Yamamoto K, Uekama K.
    Mol Pharm; 2011 Aug 01; 8(4):1276-84. PubMed ID: 21591726
    [Abstract] [Full Text] [Related]

  • 15. Possible enhancing mechanism of the cutaneous permeation of 4-biphenylylacetic acid by beta-cyclodextrin derivatives in hydrophilic ointment.
    Arima H, Miyaji T, Irie T, Hirayama F, Uekama K.
    Chem Pharm Bull (Tokyo); 1996 Mar 01; 44(3):582-6. PubMed ID: 8882455
    [Abstract] [Full Text] [Related]

  • 16. Physico-chemical characterization of disoxaril-dimethyl-beta-cyclodextrin inclusion complex and in vitro permeation studies.
    Ventura CA, Giannone I, Musumeci T, Pignatello R, Ragni L, Landolfi C, Milanese C, Paolino D, Puglisi G.
    Eur J Med Chem; 2006 Feb 01; 41(2):233-40. PubMed ID: 16387393
    [Abstract] [Full Text] [Related]

  • 17. Protective effect of sulfobutyl ether beta-cyclodextrin on DY-9760e-induced hemolysis in vitro.
    Nagase Y, Hirata M, Arima H, Tajiri S, Nishimoto Y, Hirayama F, Irie T, Uekama K.
    J Pharm Sci; 2002 Nov 01; 91(11):2382-9. PubMed ID: 12379923
    [Abstract] [Full Text] [Related]

  • 18. Development of parenteral formulation for a novel angiogenesis inhibitor, CKD-732 through complexation with hydroxypropyl-beta-cyclodextrin.
    Kim JH, Lee SK, Ki MH, Choi WK, Ahn SK, Shin HJ, Hong CI.
    Int J Pharm; 2004 Mar 19; 272(1-2):79-89. PubMed ID: 15019071
    [Abstract] [Full Text] [Related]

  • 19. Physicochemical properties of inclusion complexes of highly soluble β-cyclodextrins with highly hydrophobic testosterone propionate.
    Celia C, Scala A, Stancanelli R, Surdo E, Paolino D, Grattoni A, Micale N, Crupi V, Majolino D, Fresta M, Tommasini S, Venuti V, Ventura CA.
    Int J Pharm; 2017 Dec 20; 534(1-2):316-324. PubMed ID: 29042336
    [Abstract] [Full Text] [Related]

  • 20. Differential effects of sulfate and sulfobutyl ether of beta-cyclodextrin on erythrocyte membranes in vitro.
    Shiotani K, Uehata K, Irie T, Uekama K, Thompson DO, Stella VJ.
    Pharm Res; 1995 Jan 20; 12(1):78-84. PubMed ID: 7724491
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.